The mystery of Mercury's missing meteorites – and how we may have finally found some
It should also be physically possible for such debris to reach the Earth from Mercury, another nearby rocky body. But so far, none have been confirmed to come from there – presenting a longstanding mystery.
A new study my colleagues and I conducted has discovered two meteorites that could have a Mercurian origin. If confirmed, they would offer a rare window into Mercury's formation and evolution, potentially reshaping our understanding of the planet nearest the Sun.
Because Mercury is so close to the Sun, any space mission to retrieve a sample from there would be complex and costly. A naturally delivered fragment, therefore, may be the only practical way to study its surface directly – making such a discovery scientifically invaluable.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Observations from Nasa's Messenger mission have inferred the surface composition of Mercury. This suggests the presence of minerals known as such as sodium-rich plagioclase (such as albite), iron-poor pyroxene (for example enstatite), iron-poor olivine (such as forsterite) and sulfide minerals such as oldhamite.
The meteorite Northwest Africa (NWA) 7325 was initially proposed as a possible fragment of Mercury. However, its mineralogy includes chromium-rich pyroxene containing approximately 1% iron. This poorly matches Mercury's estimated surface composition. As a result of this, and other factors, this link has been challenged.
Aubrite meteorites have also been proposed as potential Mercurian fragments. Recent modelling of their formation suggests an origin from a large planetary body approximately 5,000km in diameter (similar to Mercury), potentially supporting this hypothesis.
Although aubrites do not exhibit chemical or spectral (the study of how light is broken up by wavelength) similarities with Mercury's surface, it has been hypothesised that they may derive from the planet's shallow mantle (the layer beneath the surface). Despite ongoing research, the existence of a definitive meteorite from Mercury remains unproven.
Our latest study investigated the properties of two unusual meteorites, Ksar Ghilane 022 and Northwest Africa 15915. We found that the two samples appear to be related, probably originating from the same parent body. Their mineralogy and surface composition also exhibit intriguing similarities to Mercury's crust. So this has prompted us to speculate about a possible Mercurian origin.
Both meteorites contain olivine and pyroxene, minor albitic plagioclase and oldhamite. Such features are consistent with predictions for Mercury's surface composition. Additionally, their oxygen compositions match those of aubrites. These shared characteristics make the samples compelling candidates for being Mercurian material.
However, notable differences exist. Both meteorites contain only trace amounts of plagioclase, in contrast to Mercury's surface, which is estimated to contain over 37%. Furthermore, our study suggests that the age of the samples is about 4,528 million years old. This is significantly older than Mercury's oldest recognised surface units, which are predicted (based on crater counting) to be approximately 4,000 million years.
If these meteorites do originate from Mercury, they may represent early material that is no longer preserved in the planet's current surface geology.
To link any meteorite to a specific asteroid type, moon or planet is extremely challenging. For example, laboratory analysis of Apollo samples allowed meteorites found in desert collection expeditions to be matched with the lunar materials. Martian meteorites have been identified through similarities between the composition of gases trapped in the meteorites with measurements of the martian atmosphere by spacecraft.
Until we visit Mercury and bring back material, it will be extremely difficult to assess a meteorite-planet link.
The BepiColombo space mission, by the European and Japanese space agencies, is now in orbit around Mercury and is about to send back high-resolution data. This may help us determine the ultimate origin body for Ksar Ghilane 022 and Northwest Africa 15915.
If meteorites from Mercury were discovered, they could help resolve a variety of long-standing scientific questions. For example, they could reveal the age and evolution of Mercury's crust, its mineralogical and geochemical composition and the nature of its gases.
The origin of these samples is likely to remain a subject of continuing debate within the scientific community. Several presentations have already been scheduled for the upcoming Meteoritical Society Meeting 2025 in Australia. We look forward to future discussions that will further explore and refine our understanding of their potential origin.
For now, all we can do is make educated guesses. What do you think?
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Ben Rider-Stokes receives funding from the Science and Technology Facilities Council (STFC).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
New Trials, New Targets: New Hope for Alzheimer's
After decades of frustration and failure, the landscape of drug development for Alzheimer's disease (AD) is starting to shift beyond anti-amyloids. Fueled by a growing pipeline of investigational agents, a broader range of therapeutic targets, and a record number of active clinical trials, a growing, but cautious, optimism is taking hold. The Alzheimer's Drug Development Pipeline 2025 reported there are currently 138 novel drugs under evaluation in 182 clinical trials — up 9% from 2024. Initiated by Jeffrey L. Cummings, MD, and colleagues in 2016, this year's annual report showed these clinical trials are being conducted at more than 4500 sites worldwide and included more than 50,000 participants. 'There's great reason for optimism. It's not just the increased amount of clinical trials, but the targeted therapies being studied,' said Cummings, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada, Nevada, in a statement. Howard Fillit, MD, cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation, agreed. 'What's going on is really quite remarkable. We have the first disease-modifying drugs on the market, which is amazing, and I think the portfolio of drugs in development has changed dramatically from even 5 years ago,' Fillit told Medscape Medical News . James Rowe, PhD, professor of cognitive neurology, University of Cambridge, Cambridge, England, was equally impressed by the latest report. 'What strikes me is not just the number of new drugs but their range of targets in which they work, giving us multiple shots on goal,' Rowe commented during a media briefing on the report. The Next Big Thing? Currently 12 phase 3 trials are expected to report results this year. In an interview with Medscape Medical News , Cummings noted that 'one of the most interesting and probably most influential of the readouts that will occur this year' involves two trials evoke and evoke+ of the GLP-1 receptor antagonist semaglutide in patients with mild cognitive impairment (MCI) or mild AD dementia. 'Semaglutide is a drug approved for diabetes and obesity, and it has epidemiologic and laboratory support for testing in Alzheimer's disease. And what's important is that this is an oral medication and it would just be fabulous if we had an oral alternative for treatment,' said Cummings. Phase 3 data on the combination of xanomeline plus trospium, a medication approved for schizophrenia in adults, which is being tested for psychosis in AD, is also highly anticipated, Cummings said. 'There are no approved treatments for psychosis in Alzheimer's disease, so this is going to be a particularly interesting readout,' he noted. Cummings also highlighted BIIB080, Biogen's investigational antisense oligonucleotide targeting tau, as another promising compound for early-stage AD. The therapy received Fast Track designation from the FDA in April. In early testing, BIIB080 reduced soluble tau protein in cerebrospinal fluid (CSF), decreased aggregated tau pathology in the brain and showed favorable trends in exploratory clinical outcomes. New data on BIIB080 is expected in 2026. Hopes are also high for trontinemab (Roche), a modified version of the anti-amyloid monoclonal antibody gantenerumab. The therapy uses brain shuttle technology to improve its ability to cross the blood-brain barrier. 'This so-called brain shuttle technology is exciting because they've found a way to get much more of the antibody across the brain barrier and into the brain and engage the target. And this technology could be used to get other drugs into the brain,' Cummings said. The Big Picture There are currently 48 trials assessing 31 drugs in phase 3; 86 trials assessing 75 drugs in phase 2; and 48 trials assessing 45 drugs in phase 1. Of the 182 trials, 16 are long-term extensions of agents in prior trials. Since the beginning of 2024, 56 new trials entered the pipeline across all phases, including 10 new phase 3 trials. A total of 12 therapeutic agents are expected to complete phase 3 trials and 29 are scheduled to complete phase 2 in 2025. Disease-targeted therapies (DTTs) continue to dominate the AD drug pipeline. Biological DTTs comprise 30% of the pipeline and small molecule DTTs account for 43%. Drugs targeting cognitive enhancement make up 14% of the pipeline and drugs aimed at ameliorating AD neuropsychiatric symptoms comprise 11%. Repurposed agents represent 33% of the pipeline agents. In addition, biomarkers are among the primary outcomes of 27% of active trials. Beyond Amyloid: New Targets Anti-amyloid agents, lecanemab and donanemab, became the first disease-targeting medications for AD and represented a 'huge leap forward in our understanding and ability to treat AD,' Sheona Scales, PhD, director of research, Alzheimer's Research UK, told reporters attending the press briefing. Scales noted that a key focus of ongoing anti-amyloid research is to find ways to increase brain exposure and reduce the side effects of these agents. Beyond anti-amyloids, the latest pipeline report showed not only numerical growth but also increased biological diversity among the agents under investigation. 'Research is revealing even more complexities around how Alzheimer's disease starts and progresses, and this goes beyond amyloid. The current therapeutic pipeline has more diverse targets than in previous years,' Scales said. Similar to 2024, this year only 18% of drugs in the pipeline target amyloid-related pathophysiology, whereas 11% target tau-related processes. 'Neuroinflammation, in particular, is a highly active area of therapeutic development,' Emma Mead, PhD, interim chief scientific officer, Oxford Drug Discovery Institute, told reporters. 'Neuroinflammation is the brain's response to injury, infection or disease, and research has suggested that in neurodegenerative conditions, microglia, the immune cells of the brain, become dysregulated and this contributes to the damage associated with Alzheimer's disease,' Mead explained. Thirty drugs (22%) in the pipeline target neurotransmitter receptors, 24 (17%) address neuroinflammation/immune processes and 6% address synaptic plasticity/neuroprotection. Combination Therapies and Prevention Given the complexity of AD, it's become clear that targeting a single pathway may not be sufficient for effective treatment. Combination therapy targeting multiple complementary pathologic mechanisms will be necessary to maximize therapeutic effects. The 2025 AD drug pipeline includes 20 trials of combination therapies, comprising 11% of all current trials. Ten of these trials target aspects of both inflammation and amyloid. For example, two trials are testing dasatinib, in combination with quercetin, as a senolytic therapy for dementia. Senescent cells accumulate with age and are believed to contribute to age-related diseases like dementia. Six trials are assessing combinations of dextromethorphan and a CYP2D6 inhibitor for reducing agitation associated with dementia. Four trials are assessing the combination of xanomeline plus trospium. 'Because Alzheimer's disease is so complex and different pathologies develop at different times across the disease course, it's likely that in the future, patients are going to be offered specific treatments that target distinct mechanistic pathways depending on their disease stage,' Mead said. Rowe said one of the most compelling findings in the latest pipeline reported as the notable increase in late-phase trials focused on prevention. These AD prevention trials aim to intervene before symptoms appear — targeting individuals at high risk due to genetics, biomarkers, or early pathological changes — to delay or even prevent clinical onset. 'The aspiration to prevent, not just treat, is starting to be seen in the figures and that's very exciting,' he told the briefing. Repurposing Current Medications? About a third of the agents currently under investigation are repurposed medications — drugs originally approved for other conditions — which may offer a faster path to patient access. They include the GLP-1 receptor agonists (RAs) used to treat diabetes and obesity. In addition to semaglutide, another GLP-1 RA, liraglutide, demonstrated a 50% reduction in brain atrophy and 18% slower cognitive decline in the phase 2b ELAD clinical trial of adults with mild to moderate AD. The diabetes medication metformin is also in phase 3 testing for AD with results expected in 2026. Antihypertensive medications — including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) — are also being studied for their potential neuroprotective effects. A randomized trial of the ARB candesartan showed positive neurocognitive effects independent of, and in addition to, their blood-pressure lowering effects. Further, a low dose formulation of the antiepileptic levetiracetam has also shown potential in the treatment of MCI and early AD by targeting hippocampal hyperactivity, a hallmark of AD. Research has also hinted that antibiotics, antivirals, some vaccines, and anti-inflammatory medications may protect against dementia, possibly by mitigating pathogen-induced neuroinflammation. Closer to a Cure? 'Trial innovation' is also evident in the 2025 AD drug development pipeline, the report's authors noted, with plasma biomarkers playing a greater role in AD diagnosis. Recent studies have suggested that plasma p-tau 217 measures are equivalent in diagnostic accuracy to CSF biomarkers of AD pathology. Several trials entering the pipeline this year are using plasma p-tau 217 to confirm AD diagnosis and serve as an eligibility criterion for clinical trial participation. In one trial, eligibility was based on Aβ 42/40 plus the ratio of p-tau 217/nonphosphorylated tau 217; a separate trial used 'blood biomarkers' or past CSF or PET evidence of Aβ abnormalities for eligibility. CSF levels of microtubule-binding region tau243 have been shown to correlate with insoluble tau detected by tau PET imaging and are being used as a primary outcome measure in an anti-tau antibody trial. 'The use of biomarkers to determine eligibility and as outcomes in clinical trials shows the increasingly important role that biomarkers play in AD drug development,' Cummings and colleagues wrote. Summing up, they said the 2025 AD drug pipeline report demonstrates 'robust' momentum toward identifying new therapies for the treatment of AD. 'Seeing the broad range of scientific research that's taking place, I am extremely hopeful that we are closer than ever to finding a cure for Alzheimer's,' Cummings said in the news release.
Medscape
an hour ago
- Medscape
Apheresis May Sweep Microplastics From Veins
Microplastics are particles ranging from 1 micrometer to 5 millimeters in diameter, and nanoplastics, which are even smaller, are found in virtually every environment on Earth, from mountain peaks to ocean depths, and from the smallest animals in the food chain to human brain cells. These particles can originate from the breakdown of larger plastic items or be intentionally manufactured for use in products, such as cosmetics, synthetic fabrics, and pharmaceuticals. Recent studies suggest that the human brain may contain up to a teaspoon of microplastics and nanoplastics, with the tiniest fragments primarily composed of polyethylene, the same material commonly used in plastic bags and food packaging. These particles have been detected in areas such as the walls of blood vessels in the brain and within immune cells. However, it remains unclear whether microplastics contribute to the progression of neurological diseases or whether these conditions render the brain more susceptible to particle infiltration. In animal studies involving fish and rodents, prolonged exposure to nanoplastics has been linked to memory impairment, brain inflammation, and alterations in synaptic protein levels. Beyond the brain, microplastics have been found in human feces, arterial plaques, and even the placenta. A study published in The New England Journal of Medicine linked the presence of microplastics in the arteries to a heightened risk for heart attack, stroke, and overall mortality. Therapeutic Apheresis According to a preliminary study published in Brain Medicine by researchers at Technische Universität Dresden in Dresden, Germany, therapeutic apheresis, a medical procedure that filters tiny particles from the blood, may help remove microplastics from the human body. The technique can capture particles as small as 200 nanometers, which is approximately 5000 times smaller than a millimeter. In this study, the researchers evaluated the procedure in patients with myalgic encephalomyelitis, also known as chronic fatigue syndrome. They analyzed the waste fluid discarded during apheresis using a specialized infrared spectroscopy technique. The analysis detected substances that matched the chemical signatures of polyamide and polyurethane, two common types of industrial plastics. This suggests that microplastics may have been successfully removed from the blood of patients during the procedure. Notably, this study did not measure the total amount of microplastics removed or compare their levels in patients before and after apheresis. What has been demonstrated so far is the presence of microplastics in the waste material discarded by the device — an observation that suggests, but does not yet confirm, the effective removal of these substances from the human body. Researchers have cautioned that the detected materials may reflect chemical structures common to proteins, meaning that further analysis is required to verify the exact nature of the removed particles. Nonetheless, the findings offer hope to researchers seeking to address the growing accumulation of microplastics in the human body. The authors recommended conducting studies with larger groups and quantitative analyses comparing the levels of microplastics in the blood before and after the procedures. The authors concluded that 'such analyses will help determine particle removal from blood and tissues and assess correlations with symptom improvement in conditions like myalgia encephalomyelitis/chronic fatigue syndrome.' Alternative Approaches Currently, evidence that microplastics are effectively removed from the human body after ingestion is limited. A 2011 study examined bisphenol A (BPA) levels in blood, sweat, and urine samples from 20 individuals. In 16 cases, BPA appeared only in sweat, suggesting that induced perspiration may help eliminate certain compounds from the body. However, more studies are needed to assess its long-term safety and efficacy. 'That is why we focus on reducing exposure to microplastics in the first place,' said Nicholas Fabiano, MD, a psychiatry resident at the University of Ottawa, Ottawa, Ontario, Canada, and co-author of a related article in Brain Medicine . The challenge of this research began with tracking the effects of microplastic particles. 'From a clinical perspective, it is very difficult to establish a direct link between exposure to microplastics and adverse health outcomes,' said Fabiano. To address this, he advocated the creation of new tools to measure dietary risks, such as a dietary microplastic index. 'We propose the development of a Dietary Microplastic Index that could be integrated with existing dietary risk assessment tools to estimate microplastic exposure based on the types of food consumed,' he said.
Digital Trends
an hour ago
- Digital Trends
The ISS menu is about to get a lot more interesting
The first person to consume food in space was Soviet cosmonaut Yuri Gagarin, who during his brief time in orbit in 1961 had the unenviable pleasure of devouring a meal of beef and liver paste squeezed from an aluminum tube. It sounds awful, because it almost certainly was. Over the decades, however, astronaut food has steadily improved, and while some dishes continue to require rehydration in foil packets, others actually bear some resemblance to what you might eat back on terra firma — although this sushi 'meal' doesn't really cut it. Recommended Videos French astronaut Sophie Adenot is one of the lucky ones. When she heads to the International Space Station (ISS) next year, she's going to be taking with her some top-class nosh created by award-winning Michelin-starred chef Anne-Sophie Pic. Taking a welcome break from freeze-dried scrambled eggs and powdered soups, Adenot and her ISS crewmates will get to enjoy tasty dishes such as parsnip velouté with curry and smoked haddock, onion soup with pink peppercorns and gratinéed croutons, and lobster bisque with crab and caraway — and they're just the starters. While most meals aboard the ISS are basic fare from cans or vacuum packs, every so often a special 'bonus meal' is prepared for all of the astronauts to enjoy together, partly to help with crew bonding, and partly to give everyone a welcome break from the blander menu items. 'During a mission, sharing our respective food is a way to invite our crewmates to discover more about our culture,' Adenot said. 'It's a very special bonding moment for all of us and a welcome change in our day-to-day routine. I have no doubt they'll be as enthusiastic as I am when they get a chance to taste Anne-Sophie's dishes.' When creating the one-off menu, Pic had to consider strict rules for food aboard the ISS. For example, dishes have to be solid or contained so that crumbs or small bits don't float away in the microgravity conditions and clog up the space station's ventilation systems. 'Cooking for space means pushing the boundaries of gastronomy,' Pic said. 'With my team in my research and development lab, we embraced a thrilling challenge: preserving the emotion of taste despite extreme technical constraints.' As NASA looks toward the first crewed missions to Mars and beyond, astronauts have also been experimenting with growing produce in microgravity, providing them with fresh food as part of a sustainable life-support system, while also boosting crew morale.
